IDEAYA Biosciences, Inc. (IDYA) Bundle
A Brief History of IDEAYA Biosciences, Inc. (IDYA)
Company Overview
IDEAYA Biosciences, Inc. is a precision medicine oncology company located in South San Francisco, California. The company went public on May 8, 2020, with an initial public offering (IPO) price of $14 per share.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2022 | $46.4 million | $93.3 million | $261.4 million |
| 2023 | $62.1 million | $85.7 million | $224.6 million |
Research and Development Focus
IDEAYA concentrates on synthetic lethality precision medicine in oncology, with key programs including:
- IDE397 (PARG inhibitor)
- IDE196 (PKC inhibitor)
- MAT2A inhibitor program
Stock Performance
As of January 2024, IDEAYA's stock (NASDAQ: IDYA) was trading at approximately $6.50 per share, with a market capitalization of around $252 million.
Partnerships
Key collaboration partners include:
- GSK (GlaxoSmithKline)
- Merck
Clinical Trials
IDEAYA has multiple ongoing clinical trials in various stages of development, focusing on precision oncology treatments.
A Who Owns IDEAYA Biosciences, Inc. (IDYA)
Major Institutional Shareholders
As of the latest available data, the following institutional shareholders own significant stakes in IDEAYA Biosciences:
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 2,214,806 shares | 9.04% |
| BlackRock Inc. | 1,947,325 shares | 7.95% |
| Federated Hermes Inc. | 1,432,692 shares | 5.85% |
| State Street Corporation | 1,287,542 shares | 5.26% |
Insider Ownership
Key insider ownership details include:
- Michael Moazami (Chief Financial Officer): 29,178 shares
- Yujiro Hata (President and CEO): 92,341 shares
- Board members collectively own approximately 3.2% of total outstanding shares
Top Mutual Fund Holders
| Mutual Fund | Shares Held | Percentage |
|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,043,256 shares | 4.26% |
| Fidelity Select Portfolios | 672,341 shares | 2.74% |
Public Float
Total public float: 24,514,672 shares
Ownership Concentration
- Top 10 shareholders own approximately 42.3% of total outstanding shares
- Institutional investors control roughly 65.7% of the company's shares
IDEAYA Biosciences, Inc. (IDYA) Mission Statement
Company Overview
IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on developing targeted therapeutics.
Financial Performance
| Metric | Value |
|---|---|
| Market Cap (as of Q4 2023) | $486.2 million |
| Annual Revenue (2022) | $47.3 million |
| Net Loss (2022) | $86.4 million |
| Cash and Investments (Q3 2023) | $292.1 million |
Research Focus Areas
- Synthetic Lethality
- DNA Damage Response (DDR) Targeting
- Precision Oncology
Key Pipeline Programs
| Program | Development Stage | Target |
|---|---|---|
| IDE397 | Phase 1/2 | PARP7 |
| IDE161 | Preclinical | WRN Helicase |
Strategic Objectives
Primary Goal: Develop innovative targeted cancer therapies with precision medicine approach.
Clinical Development
- Active clinical trials in multiple oncology indications
- Collaborations with pharmaceutical partners
- Focus on genetically defined patient populations
Investor Information
| Stock Symbol | Exchange | Stock Price (as of January 2024) |
|---|---|---|
| IDYA | NASDAQ | $8.47 |
How IDEAYA Biosciences, Inc. (IDYA) Works
Company Overview
IDEAYA Biosciences, Inc. is a precision medicine oncology company based in South San Francisco, California. The company focuses on developing targeted therapeutics for genetically defined cancers.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $534.2 million |
| Total Revenue | $47.3 million |
| Net Loss | $94.6 million |
| Cash and Investments | $261.4 million |
Research and Development Focus
- Synthetic Lethality Program
- DNA Damage Response (DDR) Inhibitors
- PARP Inhibitor Program
Key Pipeline Assets
| Drug Candidate | Indication | Clinical Stage |
|---|---|---|
| IDE397 | PARP7 Inhibitor | Phase 1/2 |
| IDE161 | KRAS G12C Inhibitor | Preclinical |
Strategic Collaborations
IDEAYA has established strategic partnerships with GSK (GlaxoSmithKline) for synthetic lethality programs and Merck for combination therapies.
Operational Metrics
- Employee Count: 142 as of December 2023
- Research Facilities: South San Francisco, California
- Public Listing: NASDAQ under ticker IDYA
Stock Performance
| Stock Metric | 2023 Value |
|---|---|
| Stock Price (December 2023) | $11.45 |
| 52-Week High | $16.87 |
| 52-Week Low | $6.12 |
How IDEAYA Biosciences, Inc. (IDYA) Makes Money
Revenue Streams
IDEAYA Biosciences generates revenue through multiple channels focused on precision oncology and targeted therapies.
| Revenue Source | 2023 Amount |
|---|---|
| Research Collaborations | $36.4 million |
| Grant Income | $5.2 million |
| License Agreements | $12.7 million |
Drug Development Portfolio
IDEAYA focuses on developing targeted therapeutics in oncology.
- IDE397 - Synthetic Lethality Program
- IDE196 - Protein Kinase C Inhibitor
- PARG Program - DNA Damage Response
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $54.3 million |
| Net Loss | $($103.6 million) |
| Cash and Investments | $276.1 million |
Strategic Partnerships
IDEAYA maintains strategic collaborations to advance drug development.
- Merck - Synthetic Lethality Partnership
- GSK - Precision Oncology Collaboration
IDEAYA Biosciences, Inc. (IDYA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.